Loading...
ZP1609/danegaptide and mitochondrial connexin hemichannels: a harbinger for peptide drug design
This article is a Commentary on Boengler K, Bulic M, Schreckenberg R, Schlüter K‐D, Schulz R (2017). The gap junction modifier ZP1609 decreases cardiomyocyte hypercontracture following ischaemia/reperfusion independent from mitochondrial connexin 43. Br J Pharmacol 174: 2060–2073. https://doi.org/10...
Saved in:
| Published in: | Br J Pharmacol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley and Sons Inc.
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5513857/ https://ncbi.nlm.nih.gov/pubmed/28567717 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13891 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|